Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
In the last 90 days, Organon & Co. insiders filed 0 open-market purchases and 1 sale; 636 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Organon & Co. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 697 | 11 | 672 | −14 |
| Shares | 213.7M | 2.10M | 199.9M | −11.6M (−5.5%) |
| Value | $2.07B | $20.3M | $2.13B | +$83.5M (+4.1%) |
11 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (65)
Institutions that held Organon & Co. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (79)
Institutions that held Organon & Co. at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (11)
Institutions that held Organon & Co. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 2,043,153 | $19.8M |
| HAP Trading, LLC | 30,433 | $294.6K |
| Avantax Advisory Services, Inc. | 10,500 | $101.6K |
| Graypoint LLC | 10,469 | $101.3K |
| Atlas Capital Advisors LLC | 451 | $4.37K |
| Oliver Lagore Vanvalin Investment Group | 92 | $1.37K |
| Semmax Financial Advisors Inc. | 122 | $1.12K |
| Parkworth Wealth Management, Inc. | 66 | $638 |
| Christopher J. Hasenberg, Inc | 8 | $77 |
| Capital A Wealth Management, LLC | 3 | $43 |
| PrairieView Partners, LLC | 13 | $0 |